PMID- 25636371
OWN - NLM
STAT- MEDLINE
DCOM- 20161101
LR  - 20161230
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 38
IP  - 5
DP  - 2015 May
TI  - [Is it possible to stop treatment with nucleos(t)ide analogs in patients with 
      e-antigen negative chronic hepatitis B? Experience and new expectations].
PG  - 305-12
LID - S0210-5705(14)00319-7 [pii]
LID - 10.1016/j.gastrohep.2014.12.001 [doi]
AB  - BACKGROUND: Treatment of HBeAg-negative chronic hepatitis B (CHB) with 
      nucleos(t)ide analogues (NA) is usually indefinite, since the loss of HBsAg, as a 
      criterion for its discontinuation, is a rare event. Recent evidence suggests that 
      discontinuing NA therapy may be feasible in selected patients. OBJECTIVES: To 
      analyze the rate of virological relapse in patients with HBeAg-negative CHB who 
      discontinued treatment with NAs. METHODS: We performed a single-center 
      observational study that included 140 patients with HBsAg-negative CHB. 
      Twenty-two patients, who received only NAs, discontinued treatment for different 
      reasons and were subsequently monitored. All had normal ALT and AST, undetectable 
      DNA and absence of cirrhosis or significant comorbidities before stopping 
      treatment. RESULTS: Twelve patients showed virologic relapse (54.54%). The mean 
      interval between discontinuation and relapse was 6.38 months (+/- 1.9) (75% 
      relapsed during the first 12 months after discontinuation). Five received 
      adefovir, 1 lamivudine and adefovir, 1 tenofovir and 5 lamivudine alone. The mean 
      treatment duration in this group was 38.5 months (+/- 4.5). The sustained response 
      group had a higher mean age and longer treatment duration than patients with 
      virologic relapse but these differences were not statistically significant. 
      CONCLUSIONS: The results suggest that NA treatment can be stopped in selected 
      patients with CHB as long as they are not cirrhotic, have completed a minimum 
      period of treatment, have normal ALT and sustained undetectable DNA. These 
      patients should be closely monitored during the first year and then indefinitely.
CI  - Copyright (c) 2014 Elsevier Espana, S.L.U. and AEEH y AEG. All rights reserved.
FAU - Martin Mateos, Rosa M
AU  - Martin Mateos RM
AD  - Servicio de gastroenterologia, Hospital Universitario Ramon y Cajal, IRYCIS, 
      Madrid, Espana. Electronic address: rosam.martinma@salud.madrid.org.
FAU - Moreira Vicente, Victor F
AU  - Moreira Vicente VF
AD  - Servicio de gastroenterologia. Hospital Universitario Ramon y Cajal, Madrid, 
      Espana; Departamento de medicina. Universidad de Alcala, Madrid, Espana.
FAU - Tavio Hernandez, Eduardo
AU  - Tavio Hernandez E
AD  - Servicio de gastroenterologia. Hospital Universitario Ramon y Cajal, Madrid, 
      Espana.
FAU - Cuno Roldan, Jose Luis
AU  - Cuno Roldan JL
AD  - Servicio de gastroenterologia. Hospital Universitario Ramon y Cajal, Madrid, 
      Espana.
FAU - Tellez Villajos, Luis
AU  - Tellez Villajos L
AD  - Servicio de gastroenterologia. Hospital Universitario Ramon y Cajal, Madrid, 
      Espana.
FAU - Aicart Ramos, Marta
AU  - Aicart Ramos M
AD  - Servicio de gastroenterologia. Hospital Universitario Ramon y Cajal, Madrid, 
      Espana.
FAU - Arribas Anta, Julia
AU  - Arribas Anta J
AD  - Servicio de gastroenterologia. Hospital Universitario Ramon y Cajal, Madrid, 
      Espana.
FAU - Zaera de la Fuente, Celia
AU  - Zaera de la Fuente C
AD  - Servicio de gastroenterologia. Hospital Universitario Ramon y Cajal, Madrid, 
      Espana.
FAU - Albillos Martinez, Agustin
AU  - Albillos Martinez A
AD  - Servicio de gastroenterologia, Hospital Universitario Ramon y Cajal, IRYCIS, 
      Madrid, Espana; Departamento de medicina. Universidad de Alcala, Madrid, Espana; 
      CIBERehd, Instituto de Salud Carlos III, Madrid, Espana.
LA  - spa
PT  - Journal Article
PT  - Observational Study
TT  -  inverted question markEs posible suspender el tratamiento con antivirales orales en los pacientes con 
      hepatitis cronica B antigeno e negativa? Experiencia y nuevas expectativas.
DEP - 20150127
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
RN  - 0 (Hepatitis B e Antigens)
RN  - 0 (Nucleotides)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alanine Transaminase/*blood
MH  - Antiviral Agents/*therapeutic use
MH  - Aspartate Aminotransferases/blood
MH  - DNA, Viral/isolation & purification
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hepatitis B e Antigens/*immunology
MH  - Hepatitis B virus/genetics/immunology/isolation & purification
MH  - Hepatitis B, Chronic/*drug therapy/immunology
MH  - Humans
MH  - Liver Cirrhosis/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Nucleotides/*therapeutic use
MH  - Recurrence
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antivirales orales
OT  - HBeAg-negative chronic hepatitis B
OT  - Hepatitis cronica B
OT  - Nucleos(t)ide analogues
OT  - Rebote virologico
OT  - virological relapse
EDAT- 2015/02/01 06:00
MHDA- 2016/11/02 06:00
CRDT- 2015/02/01 06:00
PHST- 2014/09/24 00:00 [received]
PHST- 2014/11/30 00:00 [revised]
PHST- 2014/12/01 00:00 [accepted]
PHST- 2015/02/01 06:00 [entrez]
PHST- 2015/02/01 06:00 [pubmed]
PHST- 2016/11/02 06:00 [medline]
AID - S0210-5705(14)00319-7 [pii]
AID - 10.1016/j.gastrohep.2014.12.001 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2015 May;38(5):305-12. doi: 
      10.1016/j.gastrohep.2014.12.001. Epub 2015 Jan 27.